Aaltonen LA, Salovaara R, Kristo P et al.. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481–1487.
Hampel H, Frankel WL, Martin E et al.. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851–1860.
Hampel H, Frankel WL, Martin E et al.. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008;26:5783–5788.
Kempers MJ, Kuiper RP, Ockeloen CW et al.. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 2011;12:49–55.
Rumilla K, Schowalter KV, Lindor NM et al.. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn 2011;13:93–99.
Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453–1456.
Barnetson RA, Tenesa A, Farrington SM et al.. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006;354:2751–2763.
Rodriguez-Bigas MA, Boland CR, Hamilton SR et al.. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758–1762.
Umar A, Boland CR, Terdiman JP et al.. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261–268.
Raedle J, Trojan J, Brieger A et al.. Bethesda guidelines: relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer. Ann Intern Med 2001;135:566–576.
Pinol V, Castells A, Andreu M et al.. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005;293:1986–1994.
Balmana J, Stockwell DH, Steyerberg EW et al.. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 2006;296:1469–1478.
Kastrinos F, Steyerberg EW, Mercado R et al.. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 2011;140:73–81.
Bonadona V, Bonaiti B, Olschwang S et al.. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305:2304–2310.
Moreira L, Balaguer F, Lindor N et al.. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012;308:1555–1565.
Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35–41.
Ladabaum U, Wang G, Terdiman J et al.. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011;155:69–79.
Palomaki GE, McClain MR, Melillo S et al.. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:42–65.
Balmana J, Balaguer F, Cervantes A, Arnold D. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2013;24 Suppl 6:vi73–80.
Giardiello FM, Allen JI, Axilbund JE et al.. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 2014;147:502–526.
Goodfellow PJ, Billingsley CC, Lankes HA et al.. Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for Lynch syndrome screening in endometrial cancers from GOG210: an NRG Oncology and Gynecologic Oncology Group study. J Clin Oncol 2015;33:4301–4308.
- Search Google Scholar
- Export Citation
. Goodfellow PJ Billingsley CC Lankes HA Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for Lynch syndrome screening in endometrial cancers from GOG210: an NRG Oncology and Gynecologic Oncology Group study. J Clin Oncol 2015; 33: 4301– 4308.
Marquez E, Geng Z, Pass S et al.. Implementation of routine screening for Lynch syndrome in university and safety-net health system settings: successes and challenges. Genet Med 2013;15:925–932.
Hendriks YM, de Jong AE, Morreau H et al.. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin 2006;56:213–225.
Boland CR, Thibodeau SN, Hamilton SR et al.. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248–5257.
- Search Google Scholar
- Export Citation
. Boland CR Thibodeau SN Hamilton SR A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248– 5257.
Xicola RM, Llor X, Pons E et al.. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 2007;99:244–252.
Caldes T, Godino J, Sanchez A et al.. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer. Oncol Rep 2004;12:621–629.
Vasen HF, Hendriks Y, de Jong AE et al.. Identification of HNPCC by molecular analysis of colorectal and endometrial tumors. Dis Markers 2004;20:207–213.
Hampel H, Frankel W, Panescu J et al.. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006;66:7810–7817.
Lindor NM, Burgart LJ, Leontovich O et al.. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002;20:1043–1048.
Reyes CM, Allen BA, Terdiman JP, Wilson LS. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer 2002;95:1848–1856.
Shia J, Klimstra DS, Nafa K et al.. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 2005;29:96–104.
Pino MS, Chung DC. Application of molecular diagnostics for the detection of Lynch syndrome. Expert Rev Mol Diagn 2010;10:651–665.
Stoffel EM, Mangu PB, Gruber SB et al.. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol 2015;33:209–217.
- Search Google Scholar
- Export Citation
. Stoffel EM Mangu PB Gruber SB Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol 2015; 33: 209– 217.
Rubenstein JH, Enns R, Heidelbaugh J, Barkun A. American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome. Gastroenterology 2015;149:777–782.
Haraldsdottir S, Hampel H, Tomsic J et al.. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 2014;147:1308–1316.e1301.
Engel C, Loeffler M, Steinke V et al.. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012;30:4409–4415.
Watson P, Vasen HF, Mecklin JP et al.. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008;123:444–449.
Win AK, Young JP, Lindor NM et al.. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012;30:958–964.
Win AK, Lindor NM, Young JP et al.. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst 2012;104:1363–1372.
Lindor NM, Petersen GM, Hadley DW et al.. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006;296:1507–1517.
Syngal S, Brand RE, Church JM et al.. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015;110:223–262; quiz 263.
Jenkins MA, Dowty JG, Ait Ouakrim D et al.. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis. J Clin Oncol 2015;33:326–331.
Stoffel EM, Turgeon DK, Stockwell DH et al.. Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer). Cancer Prev Res (Phila) 2008;1:470–475.
Chen LM, Yang KY, Little SE et al.. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol 2007;110:18–25.
Schmeler KM, Lynch HT, Chen LM et al.. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261–269.
Stuckless S, Green J, Dawson L et al.. Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation. Clin Genet 2013;83:359–364.
Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand 2011;90:437–444.
Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K et al.. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009;27:4793–4797.
Renkonen-Sinisalo L, Butzow R, Leminen A et al.. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007;120:821–824.
Rijcken FE, Mourits MJ, Kleibeuker JH et al.. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003;91:74–80.
Dove-Edwin I, Boks D, Goff S et al.. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002;94:1708–1712.
Dashti SG, Chau R, Ouakrim DA et al.. Female hormonal factors and the risk of endometrial cancer in Lynch syndrome. JAMA 2015;314:61–71.
Capelle LG, Van Grieken NC, Lingsma HF et al.. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010;138:487–492.
ten Kate GL, Kleibeuker JH, Nagengast FM et al.. Is surveillance of the small bowel indicated for Lynch syndrome families? Gut 2007;56:1198–1201.
Koornstra JJ, Kleibeuker JH, Vasen HF. Small-bowel cancer in Lynch syndrome: is it time for surveillance? Lancet Oncol 2008;9:901–905.
Senter L, Clendenning M, Sotamaa K et al.. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008;135:419–428.
Renkonen-Sinisalo L, Sipponen P, Aarnio M et al.. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol 2002;37:574–577.
Vasen HF, Blanco I, Aktan-Collan K et al.. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013;62:812–823.
Blaser MJ. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 1999;179:1523–1530.
Joost P, Therkildsen C, Dominguez-Valentin M et al.. Urinary tract cancer in Lynch syndrome: increased risk in carriers of MSH2 mutations. Urology 2015;86:1212–1217.
Skeldon SC, Semotiuk K, Aronson M et al.. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol 2013;63:379–385.
Wimmer K, Kratz CP, Vasen HF et al.. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘care for CMMRD’ (C4CMMRD). J Med Genet 2014;51:355–365.
Burn J, Gerdes AM, Macrae F et al.. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011;378:2081–2087.
Movahedi M, Bishop DT, Macrae F et al.. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 study. J Clin Oncol 2015.
Jankowski J, Barr H, Moayyedi P. Does aspirin really reduce the risk of colon cancer? Lancet 2012;379:1586–1587; author reply 1587.
Ait Ouakrim D, Dashti SG, Chau R et al.. Aspirin, ibuprofen, and the risk of colorectal cancer in Lynch syndrome. J Natl Cancer Inst 2015;107.